Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Citations Over TimeTop 17% of 2015 papers

Abstract

The imidazolyl-tetrahydro-β-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, telemetrized cardiovascular (CV) dogs. Herein, we describe our efforts to identify an acceptable candidate without CV effects. These efforts resulted in the identification of (1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-ethyl-pyrazol-4-yl)-1-(3-methyl-1,3,4-oxadiazol-3H-2-one-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline (17e, MK-1421).

Related Papers

• → Pathophysiology‐based phenotyping in type 2 diabetes: A clinical classification tool(2018)73 cited
• → Diabetic dermopathy and internal complications in diabetes mellitus(1998)110 cited
• [Surgical treatment of primarily diagnosed pulmonary tuberculosis in patients with diabetes mellitus].(1999)
• [Surgical treatment of tuberculosis and nonspecific lung diseases associated with diabetes mellitus].(1989)
• → P1373Assessment of atrial fibrillation cryoablation outcomes in patients with diabetes(2020)